Virology and safety profile of Molnupiravir at three different doses for treatment of SARS‐CoV‐2: a systematic review and meta‐analysis.

Molnupiravir is incorporated into the viral genome, thereby increasing errors, mismatching, and misdirecting the viral polymerase thereby, halting viral RNA replication of SARS‐CoV‐2. Following PRISMA guidelines, a thorough literature search was performed on electronic and medical databases from December 2022 till January 2023. Molnupiravir 800 mg showed significance in creating viral RNA error rate at Day 5 (WMD: 4.91; 95% CI; [1.19, 8.63] p = 0.01; I2 = 0%). Similarly, at 400 mg, Molnupiravir creates an RNA error rate (WMD: 2.27; 95% CI; 2.27 [0.50, 4.65] p = 0.02; I2 = 0%). Furthermore, exhibit a significant outcome for mean change in SARS‐CoV‐2 RNA viral load from baseline in nasopharyngeal sample at 800 mg Molnupiravir on Day 3 (WMD: −0.22; 95% CI; [−0.35, −0.08] p = 0.002; I2 = 0%), Day 5 (WMD: −0.32; 95% CI; [−0.53, −0.11] p = 0.003; I2 = 24%) and overall pooled analysis (WMD: −0.17; 95% CI; [−0.29, 0.33] p = 0.003; I2 = 32%). Moreover, Molnupiravir 400 mg significantly reduced the incidence of death compared to the placebo group (RR: 0.17; 95% CI; [0.07, 0.43] p = 0.0002; I2 = 0%). Molnupiravir effectively treats SARS‐CoV‐2 patients by eliminating the virus from the host. [ABSTRACT FROM AUTHOR]